Skip to main content
. Author manuscript; available in PMC: 2010 Sep 15.
Published in final edited form as: J Immunol. 2009 Aug 26;183(6):3598. doi: 10.4049/jimmunol.0901244

FIGURE 1.

FIGURE 1

Characterization of c264scTCR/hIL-15 fusion proteins. A, Schematic representation of the fusion protein of c264scTCR/hIL-15 or c264scTCR/hIL-15N72D. B, CTLL-2 cells were incubated with or without c264scTCR/birA or c264scTCR/hIL-15 initially and then detected with either biotinylated anti-human TCR Cβ (BF1) and PE-conjugated streptavidin (left) or PE-conjugated p53 (aa264-272)/HLA-A2 tetramer (right). C, 32Dβ cells were incubated with increasing concentrations of c264scTCR/hIL-15 (□) or recombinant hIL-15 (■) for 48 h prior to addition of WST-1 for 4 h and cell proliferation was quantitated by absorbance reading at 440 nm to assess formazan levels. The data points shown are means (±SEM) of triplicate samples and the lines represent sigmoidal dose-response curve fit for EC50 determination. The results are representative of at least three experiments.